WuXi Biologics and Fresenius struck a major biosimilar partnership aimed at scaling development and commercialization ahead of what the industry describes as a forthcoming “golden decade” for biosimilars. The arrangement is positioned as one of the largest biosimilar deals in the sector, reflecting intensified competition as biologics approach patent cliffs. The collaboration leverages WuXi Biologics’ production and development capabilities alongside Fresenius’ broader pharmaceutical footprint, aligning manufacturing capacity with demand expectations across multiple biosimilar assets. For the market, deals like this can influence timelines for filing strategies, cost structures, and the speed at which copycat products can reach patients once exclusivities end.